|
Name |
Deacetylmycoepoxydiene
|
Molecular Formula | C14H16O4 | |
IUPAC Name* |
(2R,3R)-3-hydroxy-2-[(1S,6R,7S,8R)-8-methyl-9-oxabicyclo[4.2.1]nona-2,4-dien-7-yl]-2,3-dihydropyran-6-one
|
|
SMILES |
C[C@H]1[C@@H]2C=CC=C[C@H]([C@H]1[C@@H]3[C@@H](C=CC(=O)O3)O)O2
|
|
InChI |
InChI=1S/C14H16O4/c1-8-10-4-2-3-5-11(17-10)13(8)14-9(15)6-7-12(16)18-14/h2-11,13-15H,1H3/t8-,9+,10-,11+,13-,14-/m0/s1
|
|
InChIKey |
RTPJTLADTXRGCF-OMVNPZBFSA-N
|
|
Synonyms |
Deacetylmycoepoxydiene; Deacetyl-mycoepoxydiene; PRX7MHV58V; (5S,6S)-5,6-Dihydro-5-hydroxy-6-((1R,6S,7R,8S)-8-methyl-9-oxabicyclo(4.2.1)nona-2,4-dien-7-yl)-2H-pyran-2-one; 926925-11-3; H-Pyran-2-one, 5,6-dihydro-5-hydroxy-6-((1R,6S,7R,8S)-8-methyl-9-oxabicyclo(4.2.1)nona-2,4-dien-7-yl)-, (5S,6S)-; UNII-PRX7MHV58V; 5,6-Dihydro-5beta-hydroxy-6beta-(8alpha-methyl-2alpha,7alpha-epoxycycloocta-3,5-diene-1alpha-yl)-2H-pyran-2-one
|
|
CAS | 926925-11-3 | |
PubChem CID | 91885623 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 248.27 | ALogp: | 1.4 |
HBD: | 1 | HBA: | 4 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 55.8 | Aromatic Rings: | 3 |
Heavy Atoms: | 18 | QED Weighted: | 0.713 |
Caco-2 Permeability: | -4.721 | MDCK Permeability: | 0.00001950 |
Pgp-inhibitor: | 0.014 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.019 | 20% Bioavailability (F20%): | 0.007 |
30% Bioavailability (F30%): | 0.009 |
Blood-Brain-Barrier Penetration (BBB): | 0.969 | Plasma Protein Binding (PPB): | 60.23% |
Volume Distribution (VD): | 1.714 | Fu: | 21.72% |
CYP1A2-inhibitor: | 0.2 | CYP1A2-substrate: | 0.065 |
CYP2C19-inhibitor: | 0.031 | CYP2C19-substrate: | 0.355 |
CYP2C9-inhibitor: | 0.046 | CYP2C9-substrate: | 0.082 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.208 |
CYP3A4-inhibitor: | 0.214 | CYP3A4-substrate: | 0.42 |
Clearance (CL): | 9.973 | Half-life (T1/2): | 0.879 |
hERG Blockers: | 0.206 | Human Hepatotoxicity (H-HT): | 0.376 |
Drug-inuced Liver Injury (DILI): | 0.258 | AMES Toxicity: | 0.518 |
Rat Oral Acute Toxicity: | 0.427 | Maximum Recommended Daily Dose: | 0.946 |
Skin Sensitization: | 0.354 | Carcinogencity: | 0.099 |
Eye Corrosion: | 0.005 | Eye Irritation: | 0.025 |
Respiratory Toxicity: | 0.394 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002139 | 0.692 | D02FEM | 0.223 | ||||
ENC003704 | 0.507 | D0WE3O | 0.181 | ||||
ENC005195 | 0.493 | D06WTZ | 0.180 | ||||
ENC003139 | 0.493 | D0H0ND | 0.177 | ||||
ENC003623 | 0.457 | D03DIG | 0.175 | ||||
ENC001867 | 0.405 | D0B7YT | 0.175 | ||||
ENC003403 | 0.405 | D0Z8EX | 0.173 | ||||
ENC003467 | 0.403 | D0M6VK | 0.172 | ||||
ENC003465 | 0.403 | D05ZJG | 0.172 | ||||
ENC005196 | 0.392 | D03KXY | 0.171 |